SEC Filings

424B5
AVEXIS, INC. filed this Form 424B5 on 01/16/2018
Entire Document
 

Table of Contents

 


The Offering

Common stock offered by us                shares.

Common stock to be outstanding after this offering

 

             shares.

Option to purchase additional shares

 

The underwriters have a 30-day option to purchase a maximum of             additional shares of common stock from us.

Use of Proceeds

 

We estimate that the net proceeds to us from this offering, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, will be $375.5 million, or $431.9 million if the underwriters exercise in full their option to purchase additional shares.

 

 

We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to fund our research, manufacturing and clinical activities to support our programs in SMA, Rett syndrome and ALS, to fund our pre-commercial activities, including medical affairs, development of commercial initiatives for the potential launch of AVXS-101 and licensing activities, and for general corporate purposes and working capital. See "Use of Proceeds" on page S-13.

Risk Factors

 

See the "Risk Factors" sections of this prospectus supplement and the documents incorporated by reference herein for a discussion of factors you should consider carefully before deciding to invest in our common stock.

The Nasdaq Global Select Market symbol

 

"AVXS"



          The number of shares of our common stock to be outstanding after this offering is based on 31,972,377 shares of our common stock outstanding as of September 30, 2017. This number excludes:

    3,310,475 shares of common stock issuable upon exercise of outstanding stock options as of September 30, 2017, at a weighted-average exercise price of $38.04 per share;

    87,266 shares of common stock issuable upon the settlement of outstanding restricted stock units as of September 30, 2017;

    305,775 shares of common stock issuable upon the exercise of outstanding warrants as of September 30, 2017, at a weighted-average exercise price of $2.57 per share;

    105,237 shares issued for non-cash consideration after September 30, 2017 in a transaction not registered under the Securities Act; and

    up to a maximum of 2,049,712 shares of common stock reserved for future issuance under our 2016 Equity Incentive Plan, or the 2016 Plan, as of September 30, 2017, as well as any

S-6



© AveXis, Inc. All Rights Reserved.